Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2001-08-16
2004-07-06
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S489000, C424S490000, C424S494000, C424S497000
Reexamination Certificate
active
06759058
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to enteric-coated proliposomal formulations for oral medicaments. In particular, it relates to enteric-coated proliposomal formulations for poorly water soluble drugs.
2. Description of the Related Art
Among the various routes of drug administration, the oral route is preferred because of its versatility, safety and patient comfort. The encapsulation of pharmaceuticals in liposomes is useful in reducing toxicity and improving the therapeutic effectiveness of certain drugs. For example, compounds such as insulin, factor VIII, tryptophan, phenylalanine, heparin, vitamin K etc., have been investigated for their effectiveness orally, after encapsulation into liposomes. Although they represent an improvement over the prior art, oral liposome formulations have been criticized because of their instability, leakage and potential destruction in gastric fluids.
The use of proliposomes represents an alternative to conventional liposomal formulations. Proliposomes are dry, free-flowing granular products, which, upon the addition of water, disperse to form a multilamellar liposomal suspension. The stability problems associated with conventional liposomes, including aggregation, susceptibility to hydrolysis and oxidation, may be avoided by using proliposomes. The use of proliposomes is well known in the pharmaceutical field.
Although the oral ingestion of drugs represents a safe and versatile method of pharmaceutical delivery, the therapeutic efficacy of many drugs is reduced because many pharmaceuticals are labile or inactivated under the acidic conditions of the stomach. Enteric coating materials have been applied to address this deficiency. Enteric coating materials are those that ensure that acid-labile drugs remain active in the stomach upon oral ingestion such that the active ingredient is released and absorbed in the intestine. Enteric coatings materials are well known in the pharmaceutical art and include alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and the like.
Although the use of proliposomes and the use of enteric coatings are independently known in the art, the combination of an enteric coating with a proliposomal formulation has not been disclosed. Surprisingly, when an enteric coating of the current invention is combined with a proliposomal formulation of the current invention, drug delivery is enhanced. In many embodiments of the present invent, this novel and unexpected enhancement, which results from the unique combination of an enteric coating and a proliposomal formulation, relates to increased drug absorption, stability and bioavailablity.
In many embodiments of the current invention, the combination of an enteric coating and a proliposomal formulation overcomes the disadvantages of drug delivery systems known in the prior art. For example, the utility of previous systems for orally administering labile pharmacological substances has been limited by the need to use toxic amounts of delivery agents, the instability of the systems, the inability to protect the active ingredient, the inability to effectively deliver drugs that are poorly water soluble or labile, the inadequate shelf life of the systems, the failure of the drug delivery systems to promote absorption of the active agent and the difficulties inherent to manufacturing the systems.
SUMMARY OF THE INVENTION
The current invention relates to a drug delivery system comprising at least one pharmaceutically active agent, at least one phospholipid and an enteric coating material. A particular advantage of the current invention is that it provides a simple and inexpensive system to facilitate the oral administration of medicaments. In many embodiments, this drug delivery system enhances the stability and bioavailability of pharmaceutically active agents.
In one aspect of the invention, the pharmaceutically active agent is a poorly water soluble drug.
In another aspect of the invention, the phospholipid is distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine or dimyristoyl phosphatidylcholine and the enteric coating material is cellulose acetate phthalate.
In another aspect of the invention, a pharmaceutical formulation is delivered in a tablet, capsule, suspension and/or liquid form. In alternative embodiments, carriers, diluents and/or lubricants are also included in the pharmaceutical formulation.
Another aspect of the invention relates to a method for making the drug delivery system comprising combining at least one pharmaceutically active agent with at least one phospholipid, and thereafter coating the combination with an enteric coating material. In alternate embodiments, pharmaceutically inactive agents, such as carriers, diluents and lubricants, are also included in the drug delivery system. Placebo may also be delivered according to certain embodiments of the invention.
A further aspect of the invention relates to a method for delivering a pharmaceutical formulation to a mammal by orally administering the formulation to the mammal. In specific embodiments, the current invention relates to preventing, diagnosing or treating an illness in a mammal with the drug delivery system of the present invention.
REFERENCES:
patent: 4615885 (1986-10-01), Nakagame
patent: 4849227 (1989-07-01), Cho
patent: 5206219 (1993-04-01), Desai
patent: 5505967 (1996-04-01), Geary et al.
patent: 5635206 (1997-06-01), Ganter
patent: 5665700 (1997-09-01), Cho et al.
patent: 5888550 (1999-03-01), Cook et al.
patent: 6156731 (2000-12-01), Grass et al.
patent: 6187335 (2001-02-01), Brey et al.
patent: 6309663 (2001-10-01), Patel et al.
patent: 00 87993 (1983-09-01), None
Chung SJ,Future drug delivery research in South Korea, J Control Release, Nov. 1, 1999; 62 (1-2): 73-79. Abstract in two pages.
Deo MR, Sant VP, Parekh SR, Khopade AJ, Banakar UV,Proliposome-based transdermal delivery of levonorgestrel, J Biomater Appl, Jul. 1997; 12(1): 77-88. Abstract in one page.
Perrett S, Golding M, Williams WP,A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes, J Pharm Pharmacol, Mar. 1991; 43(3): 154-161. Abstract in one page.
Katare OP, Vyas SP, Dixit VK,Effervescent granule based proliposomes of ibuprofen, J Microencapsul, Oct.-Dec. 1990; 7(4): 455-62. Abstract in one page.
Hongming Chen, Vladimir Torchillin and Robert Langer,Lectin-bearing Polymerized Liposomes as Potential Oral Vaccine Carriers, , Pharmaceutical Research, vol. 13, No. 9, 1996, pp. 1378-1383.
P. Dufour, J.C. Vuillemard, E. Laloy and R.E. Simard,Characterization of enzyme immobilization in liposomes prepared from proliposomes, J. Microencapsulation, 1996, vol. 13, No. 2, pp. 185-194.
Byung-nak ahn, Shin-Keun, Kim and chang-Koo Shim,Preparation and evaluation of proliposomes containing propranolol hydrochloride, J. Microencapsulation, 1995, No. 4, pp. 363-375.
O.P. Katare, S.P. Vyas and V.K. Dixit,Enhanced in vivo performances of liposomal Indomethacin derived from effervescent granule based proliposomes, J. Microencapsulation, 1995, vol. 12, No. 5, pp. 487-193.
Nicholas I. Payne, Peter Timmins, Cheryl V. Ambrose, Michael D. Ward and Frank Ridgway,Proliposomes: A Novel Solution to an Old Problem, Journal of Pharmaceutical Sciences, Apr. 1986, vol. 75, No. 4, pp. 325-329.
Nicholas I. Payne, Ivan Browning and Cheryl A. Hynes,Characterization of Proliposomes, Journal of Pharmaceutical Sciences, 1986, 75(4): 330-332. Abstract in one page.
Poster presented by Dr. Guru Betageri at the American Association of Pharmaceutical Scientists Meeting in Indianapolis in Nov. 2000.
Kishore Gollamudi S.
Knobbe Martens Olson & Bear LLP
Western Center for Drug Development College of Pharmacy Western
LandOfFree
Enteric-coated proliposomal formulations for poorly water... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enteric-coated proliposomal formulations for poorly water..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enteric-coated proliposomal formulations for poorly water... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3223294